For the year ending 2025-12-31, KYTX had $27,471K increase in cash & cash equivalents over the period. -$153,717K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -161,307 |
| Stock-based compensation | 10,080 |
| Accretion of discounts on available-for-sale marketable securities | 6,888 |
| Non-cash lease expense | 2,900 |
| Depreciation and amortization expense | 1,799 |
| Impairment of capitalized software | 648 |
| Non-cash interest expense | 72 |
| Loss on disposal of property and equipment | -60 |
| Prepaid expense and other current assets | -893 |
| Other non-current assets | 980 |
| Accounts payable | 543 |
| Accrued compensation | 5,107 |
| Other accrued expenses and current liabilities | -800 |
| Accrued license expense - related party | -2,500 |
| Operating lease liability | -3,339 |
| Net cash used in operating activities | -153,712 |
| Purchases of available-for-sale marketable securities | 364,623 |
| Proceeds from maturities of available-for-sale marketable securities | 405,701 |
| Internal-use software development costs | 1,128 |
| Proceeds from sale of property and equipment | 70 |
| Purchases of property and equipment | 5 |
| Net cash provided by (used in) investing activities | 40,015 |
| Proceeds from issuance of common stock upon initial public offering and underwritten public offering, net of underwriting commissions | 98,968 |
| Proceeds from issuance of common stock under the atm facility, net of agent's fees | 16,940 |
| Proceeds from borrowing of the term loan, net of issuance costs | 24,700 |
| Proceeds from exercise of common stock options | 1,987 |
| Principal paid on finance lease liabilities | 808 |
| Payments for common stock issuance offering costs | 475 |
| Taxes paid related to net share settlement upon vesting of restricted stock units | 144 |
| Net cash provided by financing activities | 141,168 |
| Net increase in cash and cash equivalents and restricted cash | 27,471 |
| Cash, cash equivalents and restricted cash, at beginning of period | 97,173 |
| Cash, cash equivalents and restricted cash, at end of period | 124,644 |
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)